Item Type | Name |
Concept
|
Treatment Outcome
|
Academic Article
|
Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery.
|
Academic Article
|
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
|
Academic Article
|
Severe hidradenitis suppurativa treated with infliximab infusion.
|
Academic Article
|
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
|
Academic Article
|
Patient education and advocacy groups: a means to better outcomes?
|
Academic Article
|
Definitions of measures of effect duration for psoriasis treatments.
|
Academic Article
|
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
|
Academic Article
|
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
|
Academic Article
|
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
|
Academic Article
|
Duration of remission of biologic agents for chronic plaque psoriasis.
|
Academic Article
|
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
|
Academic Article
|
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
|
Academic Article
|
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
|
Academic Article
|
From laboratory to clinic: rationale for biologic therapy.
|
Academic Article
|
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
|
Academic Article
|
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
|
Academic Article
|
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
|
Academic Article
|
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
|
Academic Article
|
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
|
Academic Article
|
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
|
Academic Article
|
Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul.
|
Academic Article
|
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
|
Academic Article
|
Evolution of biologic therapies for the treatment of psoriasis.
|
Academic Article
|
Remittive effects of intramuscular alefacept in psoriasis.
|
Academic Article
|
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.
|
Academic Article
|
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
|
Academic Article
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
|
Academic Article
|
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
|
Academic Article
|
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
|
Academic Article
|
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
|
Academic Article
|
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
|
Academic Article
|
Clinical meaningfulness of complete skin clearance in psoriasis.
|
Academic Article
|
Translating the Science of Psoriasis.
|
Academic Article
|
A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.
|
Academic Article
|
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
|
Academic Article
|
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
|
Academic Article
|
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
|
Academic Article
|
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
|
Academic Article
|
Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.
|
Academic Article
|
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.
|
Academic Article
|
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
|
Academic Article
|
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
|
Academic Article
|
Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
|
Academic Article
|
Safety of the new macrolide immunomodulators.
|
Academic Article
|
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
|
Academic Article
|
Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
|
Academic Article
|
Treating to Target-A Realistic Goal in Psoriasis?
|
Academic Article
|
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
|
Academic Article
|
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
|
Academic Article
|
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.
|
Academic Article
|
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
|
Academic Article
|
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
|
Academic Article
|
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
|
Academic Article
|
Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
|
Academic Article
|
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
|
Academic Article
|
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
|
Academic Article
|
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
|
Academic Article
|
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.
|
Academic Article
|
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
|
Academic Article
|
Risankizumab in moderate-to-severe plaque psoriasis.
|
Academic Article
|
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
|
Academic Article
|
Defining drug-free remission of skin disease in patients with plaque psoriasis.
|
Academic Article
|
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
|
Academic Article
|
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
|
Academic Article
|
Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
|
Academic Article
|
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
|
Academic Article
|
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
|
Academic Article
|
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
|
Academic Article
|
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
|
Academic Article
|
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
|
Academic Article
|
Efficacy, safety, usability, and acceptability of risankizumab 150?mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
|
Academic Article
|
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
|
Academic Article
|
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
|
Academic Article
|
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
|
Academic Article
|
Deucravacitinib in moderate-to-severe psoriasis.
|
Academic Article
|
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
|
Academic Article
|
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
|
Academic Article
|
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
|
Academic Article
|
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
|
Academic Article
|
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
|
Academic Article
|
Bimekizumab for the treatment of psoriasis.
|